Literature DB >> 9577370

DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR.

C Clavel1, S Rihet, M Masure, C Chypre, J C Boulanger, C Quereux, P Birembaut.   

Abstract

BACKGROUND: Oncogenicity of human papillomavirus (HPV) DNA in premalignant and malignant uterine cervical diseases is mainly induced by E6/E7 open reading frame (ORF). The presence of an oncogenic HPV DNA may be a diagnostic marker for the detection of cytologically negative smears. AIMS: To evaluate an original polymerase chain reaction enzyme immunoassay (PCR-EIA) for the detection and typing of oncogenic and non-oncogenic HPV types.
METHODS: The test was an original multiplex labelled PCR-EIA for the detection and typing of oncogenic and non-oncogenic HPV using three consensus sequence primers within the oncogenic E6/E7 ORF. One primer was dinitrophenyl (DNP) labelled and the DNP labelled amplimers could be further hybridised with specific biotinylated oligoprobes mixed in only two cocktails: oncogenic (16, 18, 31, 33, 35, 52, and 58) and non-oncogenic (6 and 11) HPV types in only two wells; then biotinylated oligoprobes were deposited in streptavidin-coated microplates. The PCR-EIA was validated on HPV plasmids (types 6, 11, 16, 18, 31, 35, 52, and 58) and used to evaluate cervical scrapes from 181 patients (median age 32 years) at high risk for cervical cancer.
RESULTS: HPV were detected in the cervical scrapes of 88 of 181 patients (48.6%); nine with non-oncogenic HPV (5.0%) and 79 with oncogenic HPV (43.6%) including 29 coinfections with oncogenic and non-oncogenic HPV. The number of oncogenic HPV infections increased with the presence of high grade lesions: 95.8% of the cervical scrapes from patients with high grade lesions contained oncogenic HPV compared with 32.1% of the specimens from patients without any lesions detectable by colposcopy and/or by cytological examination of the cervical smears. Moreover, 60% of cervical scrapes exhibiting low grade lesions contained oncogenic HPV.
CONCLUSIONS: This test is simple, specific, sensitive, safe, fast, reproducible, and easy to use in routine practice. Thus, it is possible to detect simultaneously on a simple cervical scrape, two kinds of HPV--oncogenic and non-oncogenic--in just two microplate wells with non-isotopic oligoprobes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9577370      PMCID: PMC500429          DOI: 10.1136/jcp.51.1.38

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  25 in total

Review 1.  Epidemiology of human papillomavirus (HPV) infections and their associations with genital squamous cell cancer. Review article.

Authors:  K J Syrjänen
Journal:  APMIS       Date:  1989-11       Impact factor: 3.205

2.  Amplification of human papillomavirus DNA sequences by using conserved primers.

Authors:  L Gregoire; M Arella; J Campione-Piccardo; W D Lancaster
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

3.  General primer polymerase chain reaction in combination with sequence analysis for identification of potentially novel human papillomavirus genotypes in cervical lesions.

Authors:  A J van den Brule; P J Snijders; P M Raaphorst; H F Schrijnemakers; H Delius; L Gissmann; C J Meijer; J M Walboomers
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

Review 4.  Strategies for global control of cervical cancer.

Authors:  J Pontén; H O Adami; R Bergström; J Dillner; L G Friberg; L Gustafsson; A B Miller; D M Parkin; P Sparén; D Trichopoulos
Journal:  Int J Cancer       Date:  1995-01-03       Impact factor: 7.396

5.  A new method for direct analysis of polymerase chain reaction-amplified human papillomavirus using DNA enzyme immunoassay.

Authors:  F Sangiuolo; L De Santis; A Cavicchini; U Angeloni; C Romanini; G Novelli; B Dallapiccola
Journal:  Int J Clin Lab Res       Date:  1994

6.  Fast solid support detection of human papillomavirus in in vitro amplified DNA using a DNP-anti DNP monoclonal antibody couple.

Authors:  M Baccard-Longère; B Alpha-Bazin; C Chypre; S Sauvaigo; R Téoule; P Bernard; J M Seigneurin
Journal:  J Virol Methods       Date:  1994-01       Impact factor: 2.014

7.  Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction.

Authors:  Y Fujinaga; M Shimada; K Okazawa; M Fukushima; I Kato; K Fujinaga
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

8.  A new nonisotopic detection of human papillomavirus DNA using polymerase chain reaction.

Authors:  I Binninger; C Clavel; M Polette; M C Boutterin; C Chypre; B Alpha; P Birembaut
Journal:  Diagn Mol Pathol       Date:  1992-12

9.  A polymerase chain reaction-enzyme-linked immunosorbent assay method for detecting human papillomavirus in cervical carcinomas and high-grade cervical cancer precursors.

Authors:  O Lungu; X W Sun; T C Wright; A Ferenczy; R M Richart; S Silverstein
Journal:  Obstet Gynecol       Date:  1995-03       Impact factor: 7.661

10.  Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities.

Authors:  C S Herrington; M F Evans; N F Hallam; F M Charnock; W Gray; J D McGee
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  6 in total

1.  The Use of Molecular Techniques for the Diagnosis and Epidemiologic Study of Sexually Transmitted Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

Review 2.  Multiplex PCR: optimization and application in diagnostic virology.

Authors:  E M Elnifro; A M Ashshi; R J Cooper; P E Klapper
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 3.  Human papillomavirus infection with particular reference to genital disease.

Authors:  C Sonnex
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

4.  Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus.

Authors:  B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

5.  Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions.

Authors:  C Clavel; M Masure; I Putaud; K Thomas; J P Bory; R Gabriel; C Quereux; P Birembaut
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

6.  Prevalence of human papillomavirus infection in women in Benin, West Africa.

Authors:  Franca Piras; Michela Piga; Antonella De Montis; Ahissou R F Zannou; Luigi Minerba; Maria T Perra; Daniela Murtas; Manuela Atzori; Marco Pittau; Cristina Maxia; Paola Sirigu
Journal:  Virol J       Date:  2011-11-10       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.